Stage II success for new manufacturing technology – Lidocaine
20 February 2018
Stage II success for new manufacturing technology: Lidocaine
Medical Developments International Limited (ASX: MVP) is delighted to announce that, in partnership with the CSIRO, it has successfully completed a small-scale production run for Lidocaine using MVP’s new manufacturing technology.
Lidocaine has worldwide sales of approximately $3.4 billion. It is a common local anaesthetic and antiarrhythmic drug. It is injected as a local anaesthetic for minor surgery and used as a dental anaesthetic.
For the full release, please refer to the following link ASX Announcement – Stage II success for new manufacturing technology – Lidocaine